LB Pharmaceuticals Stock (NASDAQ:LBRX)


OwnershipChart

Previous Close

$27.66

52W Range

$13.36 - $33.47

50D Avg

$29.39

200D Avg

$22.38

Market Cap

$861.73M

Avg Vol (3M)

$225.83K

Beta

0.71

Div Yield

-

LBRX Company Profile


This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

16

IPO Date

Sep 11, 2025

Website

LBRX Performance


Peer Comparison


TickerCompany
AUTLAutolus Therapeutics plc
DSGNDesign Therapeutics, Inc.
ALTAltimmune, Inc.
ANNXAnnexon, Inc.
LRMRLarimar Therapeutics, Inc.
SLDBSolid Biosciences Inc.
DBVTDBV Technologies S.A.
RCKTRocket Pharmaceuticals, Inc.
AURAAura Biosciences, Inc.
KRROKorro Bio, Inc.